This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back



Treating patients with COPD in secondary care, a discussion around triple therapy options



National guidance (NICE) has a clear recommendation for triple therapy (ICS/LABA/LAMA) for those that have been on dual therapy: For patients who have 1 severe or 2 moderate exacerbations within a year, or have day-to-day symptoms that adversely impact their quality of life1. Triple therapy, however, can be delivered in multiple different ways. The first is through multiple inhaler triple therapy, which there are over 40 different inhaler combinations for ICS/LABA + LAMA, these can include multiple device types and different inhalation techniques. The second is the single inhaler triple therapy options. This webinar will explore these different types of triple therapy available and discuss recent clinical evidence comparing different types of triple therapy, look at some of the potential financial implications, and finally look at some of the potential benefits to both patients and the environment.


    Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on +44 (0)800 221 441


    1. NICE Guidance accessed Oct 2020

    Please fill in the information below to complete registration for this event

      We will send you an email confirmation once your booking has been confirmed.

      Thanks <TITLE> <SURNAME>, your request has been sent!

        We'll send you an email confirmation once your booking has been confirmed.